"Results from the Phase Ib study in U.S. informed and provided critical knowledge for our 13-week Phase IIa study design of ASC30 oral once-daily tablet. As a small molecule, ASC30 has the potential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback